Bioregulator theory and mechanism Khavinson's bioregulator concept: Each organ produces specific regulatory peptides These peptides maintain tissue homeostasis With aging, peptide production declines Supplementing organ-specific peptides restores function Gene regulation is key mechanism How Cartalax works (theory): Enters cartilage cells (chondrocytes) Binds to specific DNA sequences Upregulates cartilage-protective genes Downregulates degradative genes Optimizes cartilage matrix production Gene expression changes: Upregulated (increased): Collagen Type II: Main cartilage structural protein Proteoglycans: Water-holding molecules Aggrecan: Cartilage compressive strength TGF-: Growth factors for cartilage Chondrocyte proliferation genes Downregulated (decreased): Matrix Metalloproteinases (MMPs): Cartilage-degrading enzymes Inflammatory cytokines: IL-1, TNF- Apoptosis genes: Prevents cartilage cell death Oxidative stress markers Mechanism comparison: Why bioregulation different: Works at DNA/gene level (root cause) Tissue-specific (only cartilage affected) Long-lasting effects (genes stay regulated) Cyclic dosing sufficient (vs continuous) Preventive and restorative Compare to other mechanisms and joint peptides
Levin R, Villanueva CM, Beene D, et al
Both support fat metabolism when combined with regular exercise and a balanced diet
As of early 2026, reports indicate that FDA reclassification efforts have been underway, with some movement toward restoring certain peptides to Category 1 status which would permit evaluated compounding under regulatory oversight
A powerful upgrade compared to standard NAC supplements and glutathione pills
Dresser on July 22, the day before the FDA meeting, for a timely legal and regulatory briefing on what to expect, what the potential outcomes could mean, and how organizations can prepare for the evolving regulatory landscape
